APA (7th ed.) Citation

R, M., A, O., H, N., Y, S., K, Y., Y, F., . . . S, O. (2025). Serum IL-6 concentration is a useful biomarker to predict the efficacy of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma. Journal of gastroenterology, 60(3), 328. https://doi.org/10.1007/s00535-024-02185-w

Chicago Style (17th ed.) Citation

R, Miura, et al. "Serum IL-6 Concentration Is a Useful Biomarker to Predict the Efficacy of Atezolizumab Plus Bevacizumab in Patients with Hepatocellular Carcinoma." Journal of Gastroenterology 60, no. 3 (2025): 328. https://doi.org/10.1007/s00535-024-02185-w.

MLA (9th ed.) Citation

R, Miura, et al. "Serum IL-6 Concentration Is a Useful Biomarker to Predict the Efficacy of Atezolizumab Plus Bevacizumab in Patients with Hepatocellular Carcinoma." Journal of Gastroenterology, vol. 60, no. 3, 2025, p. 328, https://doi.org/10.1007/s00535-024-02185-w.